NCT03582943 is a Phase 1 clinical trial of RLIC in Adults, sponsored by Washington University School of Medicine.

Who is sponsoring NCT03582943?

NCT03582943 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT03582943?

Interventions in NCT03582943: RLIC, Sham conditioning, Balance training.

What condition does NCT03582943 study?

NCT03582943 studies Adults, Older Adults.

Is NCT03582943 still recruiting?

NCT03582943 is currently completed. Last updated 24 October 2018.

Are results published for NCT03582943?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-10-24 · How we verify

NCT03582943

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of RLIC on Motor Learning in Middle-aged and Older Adults

Completed Phase 1 Results posted Last updated 24 October 2018

What this trial tests

Phase 1 trial testing RLIC in Adults in 82 participants. Completed in 1 October 2017.

Timeline

20 October 2015

Primary endpoint
15 September 2017

1 October 2017

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	82
Start date	20 October 2015
Primary completion	15 September 2017
Estimated completion	1 October 2017
Sites	1 location across United States

Drugs / interventions tested

RLIC
Sham conditioning
Balance training

Conditions studied

Adults — all drugs for Adults →
Older Adults — all drugs for Older Adults →

Sponsor

Washington University School of Medicine

Who can join

Adults 40 to 80, any sex, with Adults or Older Adults. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Balance Score Primary · 1 week

Balance score at the end of training - balance score at baseline, where balance score is the average amount of time in seconds that a participant maintains the stability platform within ±3° of horizontal position during 5 trials of 30 seconds each. Five trials are averaged to form the balance score at each time point.

Group	Value	95% CI
Remote Limb Ischemic Conditioning (RLIC)	5.55	± 4.85
Sham Conditioning	4.81	± 3.47

Sponsor's own description

The purpose of this research is to determine if the beneficial effects of remote limb ischemic conditioning on learning seen in young adults are found in middle-aged and older adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Remote Limb Ischemic Conditioning and Motor Learning: Evaluation of Factors Influencing Response in Older Adults.
Sutter EN, Mattlage AE, Bland MD, Cherry-Allen KM, et al · · 2019 · cited 11× · PMID 30088217 · DOI 10.1007/s12975-018-0653-8

Verify or expand the search:

Other trials of RLIC

Trials testing the same drug.

NCT04598711 — Ischemic Conditioning to Enhance Function (I-C-FUN) in Children With Cerebral Palsy · NA · completed
NCT03512028 — Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults · Phase 1 · completed

Other recruiting trials for Adults

Currently open trials in the same condition.

NCT07150117 — Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN) · NA · recruiting
NCT07482371 — Comparative Effects of Scooping Mobilization and Dynamic Cupping Therapy on Elbow Stiffness · NA · recruiting
NCT07033897 — Adapting, Implementing and Evaluating the Effectiveness of HARP for People With Disabilities · NA · recruiting
NCT06983782 — A Feasibility Randomised Controlled Trial of an Online Exercise Programme for Adults With Cerebral Palsy · NA · recruiting
NCT07285954 — Mindfulness Walking Intervention to Enhance Resilience (iWalk) · NA · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03582943 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 24 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03582943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing